|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In vivo studies showed that MP treatment activated PPARα expression, that in turns, promoted β-oxidation protein and gene expressions, suppressed TNFα, MCP1, TGFβ1 and Colla1 protein and gene expression levels, contributing to the prevention of NASH.
|
30579258 |
2019 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
The positive effects observed for SAR on NASH are due to the downregulation of the LPS/TLR4 pathway, as indicated by the suppression of hepatic Toll-like receptor 4 (TLR4), NF-κB, TNF-α, and transforming growth factor-β1 (TGF-β1) expression.
|
30737662 |
2019 |
|
Fatty Liver Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
Statistically, there was a significant association of the expressions of Shh and TGF-β1 proteins in NASH (r=0.6, P<0.05).
|
30720468 |
2019 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
A significant decrease was found in the hepatic expression of the SHH, IHH, and TGF-β1 pathways along with the expression of TAZ in tissue specimens with simple steatosis in comparison with patients affected by NASH cirrhosis and controls.
|
31087761 |
2019 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Nicotine induction of hHSC proliferation, upregulation of collagen1-α2 and the pro-fibrogenic cytokine transforming growth factor beta 1 (TGF-β1) was determined along with involved intracellular signaling pathways. nAChR mRNA expression was finally analyzed in whole liver biopsies obtained from patients diagnosed with non-alcoholic steatohepatitis (NASH).
|
22108052 |
2012 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Nonalcoholic steatohepatitis (NASH), when compared with simple steatosis (SS), significantly increases the expression of TGFB1 (6.8, p<0.005), angiotensin I-converting enzyme (ACE) (2.1, p<0.007), LAMA1 (2.1, p<0.007), SERPINB2 (2.1, p<0.007), CSF2 (2.5, p<0.002), IL1A (2.5, p<0.005), IL3 (2.1, p<0.007), IL4 (2.1, p<0.007), LIF (2.1, p<0.007), and MMP1 (2.1, p<0.007), and decreases the transcript levels of genes involved in the negative regulation of cell-death pathways.
|
21664615 |
2011 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
There was a marked increase in gene expression of TGF-beta1 in patients with NASH (P=0.0002).
|
17032406 |
2006 |